Ultragenyx’s Augmented Momentum: Unveiling Nasdaq Listing Rule 5635(c)(4) Inducement Grant – August 18, 2023

Ultragenyx Pharmaceutical Inc., a visionary biopharmaceutical firm committed to revolutionizing treatments for rare and ultra-rare ailments, has just unveiled an exciting development. In a bold move, the company has granted a total of 42,840 restricted stock units of its common stock to 18 exceptional non-executive officers who have recently joined its ranks. This remarkable gesture comes after receiving the green light from the company’s forward-thinking compensation committee.

The grants, a product of the Ultragenyx Employment Inducement Plan, were officially bestowed on August 16, 2023. This strategic maneuver not only highlights Ultragenyx’s dedication to attracting top-tier talent but also falls perfectly in line with Nasdaq Listing Rule 5635(c)(4), showcasing the company’s unwavering commitment to growth and innovation.

In a captivating dance between dedication and reward, the restricted stock units embark on a four-year journey of transformation. Picture this: a quarter of the underlying shares springing to life on each mesmerizing anniversary of the grant date. But here’s the catch—the magic only fully unfolds for those who walk hand in hand with the company, their commitment unwavering as they traverse the path of innovation.

It’s a narrative of perseverance, where every vested share becomes a testament to the enduring partnership between employee and enterprise. As time weaves its tapestry, these shares become more than numbers—they embody the spirit of ambition and the promise of a shared future.

About Ultragenyx Pharmaceutical Inc.

At the heart of medical innovation beats Ultragenyx—a biopharmaceutical trailblazer on a mission to transform lives. With unwavering dedication, the company crafts new possibilities for patients battling the shadows of rare and ultra-rare genetic diseases. Imagine a canvas painted with hope: a rich tapestry of approved therapies and promising candidates that target diseases standing at the crossroads of urgent need and profound biology.

In realms where answers are scarce, Ultragenyx emerges as a beacon of possibility, forging ahead where no approved solutions exist. Every breakthrough is a testament to their relentless pursuit—a symphony of science and compassion harmonizing to rewrite the story of medical possibility.

At the helm of this groundbreaking voyage stands a visionary management team, their expertise a compass guiding the way in the realm of rare disease therapeutics. Imagine a symphony of minds finely tuned to the rhythm of development and commercialization, orchestrating a masterpiece of innovation.

The heartbeat of Ultragenyx’s strategy? A pledge to the dance of time and cost, where drug development becomes an art of efficiency, all in service of a singular purpose: to deliver hope-fueled, life-changing therapies with an unwavering sense of urgency. It’s a journey painted with determination, where every step forward redefines what’s achievable in the realm of medical marvels.

Leave a Comment